Analysts See $-0.20 EPS for Mesoblast Limited (MESO)

May 10, 2018 - By Ellis Scott

Mesoblast Limited (NASDAQ:MESO) Logo

Analysts expect Mesoblast Limited (NASDAQ:MESO) to report $-0.20 EPS on May, 23.They anticipate $0.08 EPS change or 66.67 % from last quarter’s $-0.12 EPS. After having $-0.10 EPS previously, Mesoblast Limited’s analysts see 100.00 % EPS growth. The stock increased 0.72% or $0.04 during the last trading session, reaching $5.6. About 14,834 shares traded. Mesoblast Limited (NASDAQ:MESO) has declined 36.60% since May 10, 2017 and is downtrending. It has underperformed by 48.15% the S&P500.

Mesoblast Limited develops cell-based medicines. The company has market cap of $522.12 million. The firm has leveraged its proprietary technology platform based on mesenchymal lineage adult stem cells to establish a portfolio of late-stage product candidates. It currently has negative earnings. The Company’s allogeneic cell product candidates target advanced stages of diseases with high and unmet medical needs, including cardiovascular conditions, immunologic and inflammatory conditions, orthopedic disorders, and oncology and hematology conditions.

More notable recent Mesoblast Limited (NASDAQ:MESO) news were published by: which released: “Mesoblast Aims For Non-Addictive Opioid Substitute: CEO Itescu” on April 26, 2018, also with their article: “Facebook Tries to Curb Fake News, Abuse with New Guidelines” published on April 25, 2018, published: “Mesoblast Phase 3 Trial Results for Acute Graft Versus Host Disease Presented at 2018 International Society for Cell …” on May 08, 2018. More interesting news about Mesoblast Limited (NASDAQ:MESO) were released by: and their article: “Mesoblast Cell Therapies Featured at Vatican International Healthcare Conference” published on May 01, 2018 as well as‘s news article titled: “Mesoblast Clinical Program Update for MPC-150-IM in Patients With Chronic Heart Failure” with publication date: April 18, 2018.

Mesoblast Limited (NASDAQ:MESO) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: